HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cosmetics Reform In, Dietary Supplements Out Of US Omnibus Spending Bill

Executive Summary

The must-pass federal spending bill includes the Modernization of Cosmetics Regulation Act, which previously appeared as a rider in US Food and Drug Administration user-fee legislation but was cut from the final iteration.

You may also be interested in...



Testing Lab Advises Allergic To Check Cosmetic Product Labels For Common Food Ingredients

Sesame, milk, sunflower and apricot are among the most common food ingredients found in cosmetic products, posing potential risks to those with allergies, YorkTest suggests.

Anti-Counterfeiting INFORM Consumers Act Cheered By Personal Care, Consumer Health Industries

The Personal Care Products Council and the Consumer Healthcare Products Association say the INFORM Consumers Act’s inclusion in US Congress’ December 2022 omnibus spending package is a win for consumers and industry.

Compliance Clock Starts Ticking Under Historic Modernization of Cosmetic Regulations Act

Companies have one year to comply with US FDA registration and product listing requirements under the Modernization of Cosmetic Regulations Act of 2022, part of the $1.7tr omnibus spending package signed by President Joe Biden on 29 December. Trade groups applauded the historic milestone and the legislation’s departure from previous proposals, including the elimination of user fees.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153219

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel